Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
about
CCR5 monoclonal antibodies for HIV-1 therapyNeutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitorsBinding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonistsPotent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding SiteTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryStructural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico studyClassification of anti-HIV compounds using counterpropagation artificial neural networks and decision trees.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsNovel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.HIV entry inhibitors and their potential in HIV therapyA pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitorsClinical use of CCR5 inhibitors in HIV and beyondHIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropismHIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entrySusceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitorsReplication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTUse of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitorsCharacterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases.Maraviroc in the treatment of HIV infection.Pharmacological modulation of chemokine receptor function.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Chemokine receptor modeling: an interdisciplinary approach to drug design.
P2860
Q22242739-79646C6C-846E-4894-9028-2212F8C57176Q24655129-E94A7899-168B-49E5-9103-7041495875AEQ24658283-27015D48-6F92-432C-8C52-0E17A7E5EAF2Q24673555-D2A9A8A2-1CD2-4319-B903-D217149BF984Q27681568-00052252-83E2-49F3-839B-EC2E5679CD45Q28475912-B32F8E2A-D8C5-4203-A44A-877323ABF23DQ28481687-90D5813E-1C2B-42BA-83AE-BC072AA140DAQ31039195-3844987F-0279-4627-B5C3-369231227BC8Q33725702-6CDD48E9-7E5E-4182-9873-3DF6C167BE09Q33890786-CA202DF1-96AA-4BC9-9A6D-C2C20C602477Q33961704-A0DD48E0-8F62-4774-AEE5-A7EEA9606CC8Q33990552-B41F3B4F-3A46-4523-A654-E685F8D4BA53Q34483653-47399452-A03E-42FC-91A3-8706BF70DA25Q34571010-D6226963-8E0C-427A-A5BF-A0A740CE767CQ34595921-0BE3B717-2258-40A7-AB5D-7BAFF1F5AA2EQ34606129-9782E2F7-6E57-42C9-9211-CCD15536FBB1Q34610959-C0EC7C0A-7A70-4BCB-A4D0-2A6D95ACCA37Q34641781-39805078-5CE2-44D8-9AD1-9D7A915A3577Q35018145-3B975F6B-FA34-45F5-93FC-98B8465A6BC3Q35076868-D533A3AF-3C4C-4B60-9EAB-9107943229A2Q35554970-F1A2D3D9-BC85-415C-931B-7DD6EAE4B5E2Q35904711-6F4924E6-A6C2-4456-93C3-59D7023A89C8Q36098903-BDAD95BD-252A-4073-A276-6B9AC522457DQ36246273-B1BF7F13-AAFC-4D48-8658-F94202499EAAQ36296739-B8FFC0E7-DB5A-4269-A710-987CFABDFC98Q36607127-1B98B1E3-0110-42B0-A541-E5B5368B7790Q36827946-6DBE8629-0441-4432-AA42-B79290715EE4Q36900010-10F3807D-828A-4BDB-B43A-75DEDB81B169Q36911645-5165CAD8-7842-4BC6-A602-376C53E52FFBQ37026646-AD208A23-91DD-4BE4-A452-EF27ED9A59C6Q37071732-B275AABC-7493-48B8-80F0-B036055A7013Q37092774-E94F328A-576A-4034-AA69-C4BEFBE34EA6Q37145319-16D119B8-A9C2-427B-836B-03D62B3A7B30Q37421895-165DF4BA-9DFA-45A3-B2D1-7B938232A1D1Q37452124-158F8CDA-D07E-43E7-B12E-4EB42650AD4EQ37599363-4CB2C148-3821-4854-8A5F-5441D91DE7D3Q37634319-24467690-A476-435F-8DAD-DFA070434AF3Q37893687-646AC3E8-2A6D-4E1A-873B-838338F880E6Q38076139-CE4AE346-750D-414C-90B8-25D7FF4ACF4CQ38172960-DD40FB33-EA48-4D48-AF47-C923A9662CD7
P2860
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@en
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@nl
type
label
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@en
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@nl
prefLabel
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@en
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@nl
P2093
P1433
P1476
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
@en
P2093
Anandan Palani
Bahige M Baroudy
Christoph Seibert
Fotini Tsamis
Jayaram R Tagat
John P Moore
John W Clader
Shawn E Kuhmann
Steven O Smith
Stuart W McCombie
P356
10.1016/J.VIROL.2006.01.018
P407
P577
2006-02-21T00:00:00Z